|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||137.23 - 139.72|
|52 Week Range||96.93 - 147.17|
|PE Ratio (TTM)||43.00|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Celgene became a biotech juggernaut thanks to a treatment for tricky blood cancers. Now drugs battling lupus, MS and more are on the stock’s potential hit list.
Immune Design (IMDZ) plans to initiate a pivotal phase III study to support a Biologics License Application (BLA) for CMB305.
The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, Monsanto, Adaptimmune Therapeutics and Celgene
GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.
Bayer Aktiengesellschaft (BAYRY) inked a deal to sell selected Crop Science businesses to BASF for EUR 5.9 billion to as a part of its strategy to complete the planned acquisition of Monsanto Co.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Celgene Corp. Here are 5 ETFs with the largest exposure to CELG-US. Comparing the performance and risk of Celgene Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Celgene Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?
Nimbus Therapeutics, which struck a $1.2 billion deal to sell a drug program focused on liver diseases to Gilead Sciences Inc. last year, has formed a new immunology collaboration with Celgene Corp.
Valeant Pharmaceuticals International, Inc. (VRX) announced encouraging results from the long-term phase III extension study, AMAGINE-2 on psoriasis drug Siliq.
Shares of Intercept Pharmaceuticals (ICPT) have plunged 37% in the year so far due to safety issues regarding approved drug Ocaliva.
Mallinckrodt plc (MNK) announced that it will initiate a new phase IV study on H.P. Acthar Gel as a therapy option in patients with symptomatic sarcoidosis.
In the past 3 weeks, MannKind has tripled to $6.75, bringing the year-to-date return on Nate Pile's fund to 34.82%. Here's what's behind MannKind's strong gains and what Nate is doing about it.
Amgen (AMGN) announced that the FDA has accepted its regulatory application in the U.S. seeking label expansion for Prolia for treating patients with glucocorticoid-induced osteoporosis (GIOP).
Only one-third of 1% of Americans had such high prescription costs last year, but they account for more than a fifth of the spending in the category.
With another challenge cropping up for Teva (TEVA) in the form of earlier-than-expected generic competition for the 40 mg dose of Copaxone, here is a look at 5 drug stocks that look better-positioned.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting CELG. Over the last one-month, outflows of investor capital in ETFs holding CELG totaled $7.31 billion.
Navient (NAVI) was the biggest loser amid the S&P 500 on October 5. Navient started the week on a weaker note and traded weakly for the first three trading days.